What Is One of the Best Pharmaceutical Stocks to Buy Right Now?

AbbVie demonstrated strong financial performance with 12 blockbuster drugs generating nearly $47 billion in 2024 and recent quarterly net revenue increasing 7% to $15.4 billion, alongside a 12% rise in non-GAAP EPS to $2.97. The pharmaceutical giant, also a Dividend King with a 3% yield, maintains robust free cash flow, positioning it as a stable income play. Despite the author's bullish outlook, The Motley Fool's Stock Advisor team did not include AbbVie in their top 10 recommendations, suggesting alternative high-growth opportunities may exist.

Analysis

AbbVie demonstrates robust financial health, underpinned by a diverse and profitable drug portfolio. The company reported a nearly 7% year-over-year increase in net revenue to $15.4 billion in its most recent quarter, with non-GAAP earnings per share growing a more substantial 12% to $2.97. This performance is driven by a strong product lineup that included 12 blockbuster drugs in 2024, which collectively accounted for nearly $47 billion in net revenue. AbbVie's financial stability is further highlighted by its significant free cash flow, which has consistently ranged from $16.8 billion to $24.2 billion over the past five years. This cash generation supports its status as a 'Dividend King,' with a current quarterly payout of $1.64 per share yielding just under 3%, well above the S&P 500 average. While the article notes general industry risks like patent cliffs, the main counterpoint presented is AbbVie's exclusion from a specific 'top 10' stock list, suggesting that some analysts may see higher growth potential elsewhere despite AbbVie's solid fundamentals and shareholder returns.

Key Decisions for Investors

• For income-oriented investors, AbbVie's 'Dividend King' status and a yield near 3% make it a strong consideration for a core portfolio holding focused on stable capital returns.
• Investors should weigh the company's steady single-digit revenue growth and strong free cash flow against its potential for lower total returns compared to more aggressive growth-focused stocks.
• It is prudent to monitor the company's pipeline developments and the sales trajectory of key products like Skyrizi, as patent expirations remain a fundamental long-term risk factor in the pharmaceutical sector.